TWI317358B - Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators - Google Patents

Info

Publication number

TWI317358B

TWI317358B TW091133318A TW91133318A TWI317358B TW I317358 B TWI317358 B TW I317358B TW 091133318 A TW091133318 A TW 091133318A TW 91133318 A TW91133318 A TW 91133318A TW I317358 B TWI317358 B TW I317358B

Authority

TW

Taiwan

Prior art keywords

group

phenyl

cns

compound

intellectual property

Prior art date

2001-11-08

Links

• Espacenet
• Global Dossier
• Discuss

• 102000004378 Melanocortin Receptors Human genes 0.000 title claims description 20
• 108090000950 Melanocortin Receptors Proteins 0.000 title claims description 20
• YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical class C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 title 1
• 150000001875 compounds Chemical class 0.000 claims description 141
• -1 discate Substances 0.000 claims description 84
• 239000000203 mixture Substances 0.000 claims description 43
• 230000003902 lesion Effects 0.000 claims description 36
• 125000000217 alkyl group Chemical group 0.000 claims description 32
• 210000002374 sebum Anatomy 0.000 claims description 31
• 125000001424 substituent group Chemical group 0.000 claims description 24
• 230000002079 cooperative effect Effects 0.000 claims description 20
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
• 150000003839 salts Chemical class 0.000 claims description 18
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 16
• 239000008103 glucose Substances 0.000 claims description 16
• 239000008194 pharmaceutical composition Substances 0.000 claims description 16
• 125000003545 alkoxy group Chemical group 0.000 claims description 15
• 201000010099 disease Diseases 0.000 claims description 15
• 239000002253 acid Substances 0.000 claims description 12
• 229910052739 hydrogen Inorganic materials 0.000 claims description 12
• 239000001257 hydrogen Substances 0.000 claims description 12
• 206010000496 acne Diseases 0.000 claims description 11
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
• 238000004519 manufacturing process Methods 0.000 claims description 11
• 208000002874 Acne Vulgaris Diseases 0.000 claims description 10
• 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 claims description 9
• 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 claims description 9
• 239000003937 drug carrier Substances 0.000 claims description 9
• 201000004624 Dermatitis Diseases 0.000 claims description 8
• 230000001154 acute effect Effects 0.000 claims description 8
• 230000001684 chronic effect Effects 0.000 claims description 8
• 239000007789 gas Substances 0.000 claims description 8
• 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 7
• 208000008589 Obesity Diseases 0.000 claims description 7
• 210000004369 blood Anatomy 0.000 claims description 7
• 239000008280 blood Substances 0.000 claims description 7
• 230000001815 facial effect Effects 0.000 claims description 7
• 210000004907 gland Anatomy 0.000 claims description 7
• 230000001404 mediated effect Effects 0.000 claims description 7
• 235000020824 obesity Nutrition 0.000 claims description 7
• 208000024891 symptom Diseases 0.000 claims description 7
• 239000012049 topical pharmaceutical composition Substances 0.000 claims description 7
• 206010050337 Cerumen impaction Diseases 0.000 claims description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 6
• 208000001840 Dandruff Diseases 0.000 claims description 6
• 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 6
• 206010013774 Dry eye Diseases 0.000 claims description 6
• 102000030612 Melanocortin 5 receptor Human genes 0.000 claims description 6
• 108010088565 Melanocortin 5 receptor Proteins 0.000 claims description 6
• 210000002939 cerumen Anatomy 0.000 claims description 6
• 230000001771 impaired effect Effects 0.000 claims description 6
• 230000003248 secreting effect Effects 0.000 claims description 6
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 5
• 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 5
• 206010013786 Dry skin Diseases 0.000 claims description 5
• 208000010228 Erectile Dysfunction Diseases 0.000 claims description 5
• 206010016936 Folliculitis Diseases 0.000 claims description 5
• 206010017533 Fungal infection Diseases 0.000 claims description 5
• 208000033679 diabetic kidney disease Diseases 0.000 claims description 5
• 230000037336 dry skin Effects 0.000 claims description 5
• 208000002557 hidradenitis Diseases 0.000 claims description 5
• 201000001881 impotence Diseases 0.000 claims description 5
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
• 238000002156 mixing Methods 0.000 claims description 5
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 5
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 4
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 3
• 206010015150 Erythema Diseases 0.000 claims description 3
• 108010021433 Type 3 Melanocortin Receptor Proteins 0.000 claims description 3
• 102000008318 Type 3 Melanocortin Receptor Human genes 0.000 claims description 3
• 239000001177 diphosphate Substances 0.000 claims description 3
• XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 3
• 235000011180 diphosphates Nutrition 0.000 claims description 3
• 231100000321 erythema Toxicity 0.000 claims description 3
• 150000002500 ions Chemical class 0.000 claims description 3
• 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 3
• 125000003396 thiol group Chemical group [H]S* 0.000 claims description 3
• 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 2
• 230000032683 aging Effects 0.000 claims description 2
• MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 2
• 125000005059 halophenyl group Chemical group 0.000 claims 2
• GHGPIPTUDQZJJS-UHFFFAOYSA-N (2-chlorophenyl)hydrazine Chemical compound NNC1=CC=CC=C1Cl GHGPIPTUDQZJJS-UHFFFAOYSA-N 0.000 claims 1
• 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 1
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
• 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
• 208000006558 Dental Calculus Diseases 0.000 claims 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
• 229930091371 Fructose Natural products 0.000 claims 1
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
• 239000005715 Fructose Substances 0.000 claims 1
• 241000534944 Thia Species 0.000 claims 1
• 208000015114 central nervous system disease Diseases 0.000 claims 1
• 229910052740 iodine Inorganic materials 0.000 claims 1
• 239000011630 iodine Substances 0.000 claims 1
• 229920005610 lignin Polymers 0.000 claims 1
• 208000030159 metabolic disease Diseases 0.000 claims 1
• 208000017520 skin disease Diseases 0.000 claims 1
• 210000004027 cell Anatomy 0.000 description 38
• 238000000034 method Methods 0.000 description 36
• 238000012360 testing method Methods 0.000 description 35
• 125000003118 aryl group Chemical group 0.000 description 33
• 239000002585 base Substances 0.000 description 31
• 238000011282 treatment Methods 0.000 description 27
• 125000001072 heteroaryl group Chemical group 0.000 description 20
• 108010008364 Melanocortins Proteins 0.000 description 18
• 150000002632 lipids Chemical class 0.000 description 18
• 239000002609 medium Substances 0.000 description 18
• 210000003491 skin Anatomy 0.000 description 18
• 238000004458 analytical method Methods 0.000 description 17
• 201000001119 neuropathy Diseases 0.000 description 17
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 16
• 230000007823 neuropathy Effects 0.000 description 16
• 208000033808 peripheral neuropathy Diseases 0.000 description 16
• 125000003710 aryl alkyl group Chemical group 0.000 description 15
• 238000006243 chemical reaction Methods 0.000 description 15
• 239000002865 melanocortin Substances 0.000 description 15
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 14
• 238000007639 printing Methods 0.000 description 14
• 239000000243 solution Substances 0.000 description 14
• 210000001519 tissue Anatomy 0.000 description 14
• 230000015572 biosynthetic process Effects 0.000 description 13
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 13
• 239000002689 soil Substances 0.000 description 13
• 101100257999 Danio rerio stambpa gene Proteins 0.000 description 12
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
• 230000000694 effects Effects 0.000 description 12
• 230000005764 inhibitory process Effects 0.000 description 12
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
• 210000001732 sebaceous gland Anatomy 0.000 description 12
• 101150076714 stambp gene Proteins 0.000 description 12
• 238000003786 synthesis reaction Methods 0.000 description 11
• 239000003981 vehicle Substances 0.000 description 11
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
• 241001465754 Metazoa Species 0.000 description 10
• 229910052799 carbon Inorganic materials 0.000 description 10
• 239000003795 chemical substances by application Substances 0.000 description 10
• 238000002474 experimental method Methods 0.000 description 10
• 239000000499 gel Substances 0.000 description 10
• 239000007787 solid Substances 0.000 description 10
• 239000000725 suspension Substances 0.000 description 10
• 125000003342 alkenyl group Chemical group 0.000 description 9
• 150000001412 amines Chemical class 0.000 description 9
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 9
• 230000000626 neurodegenerative effect Effects 0.000 description 9
• 102000005962 receptors Human genes 0.000 description 9
• 108020003175 receptors Proteins 0.000 description 9
• 210000004378 sebocyte Anatomy 0.000 description 9
• 239000012981 Hank's balanced salt solution Substances 0.000 description 8
• 241000699666 Mus <mouse, genus> Species 0.000 description 8
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 8
• 125000000304 alkynyl group Chemical group 0.000 description 8
• 239000002775 capsule Substances 0.000 description 8
• 230000037406 food intake Effects 0.000 description 8
• 235000012631 food intake Nutrition 0.000 description 8
• 125000005842 heteroatom Chemical group 0.000 description 8
• 230000001817 pituitary effect Effects 0.000 description 8
• 230000000007 visual effect Effects 0.000 description 8
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 7
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
• 239000007995 HEPES buffer Substances 0.000 description 7
• 239000004480 active ingredient Substances 0.000 description 7
• 125000003282 alkyl amino group Chemical group 0.000 description 7
• 230000027455 binding Effects 0.000 description 7
• 230000008859 change Effects 0.000 description 7
• 125000000753 cycloalkyl group Chemical group 0.000 description 7
• 210000000256 facial nerve Anatomy 0.000 description 7
• 239000001963 growth medium Substances 0.000 description 7
• 230000033001 locomotion Effects 0.000 description 7
• 239000000843 powder Substances 0.000 description 7
• 210000002966 serum Anatomy 0.000 description 7
• OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 6
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 6
• 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 6
• 241000699670 Mus sp. Species 0.000 description 6
• 241000283973 Oryctolagus cuniculus Species 0.000 description 6
• 241000700159 Rattus Species 0.000 description 6
• 125000003277 amino group Chemical group 0.000 description 6
• 238000003556 assay Methods 0.000 description 6
• 150000001721 carbon Chemical group 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 230000000875 corresponding effect Effects 0.000 description 6
• 239000000284 extract Substances 0.000 description 6
• 230000012010 growth Effects 0.000 description 6
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
• 239000004615 ingredient Substances 0.000 description 6
• 230000006372 lipid accumulation Effects 0.000 description 6
• 210000005036 nerve Anatomy 0.000 description 6
• 210000004940 nucleus Anatomy 0.000 description 6
• 239000011541 reaction mixture Substances 0.000 description 6
• 238000011084 recovery Methods 0.000 description 6
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
• 230000004936 stimulating effect Effects 0.000 description 6
• 241000283690 Bos taurus Species 0.000 description 5
• 101800000414 Corticotropin Proteins 0.000 description 5
• 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 5
• 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 5
• 101710200814 Melanotropin alpha Proteins 0.000 description 5
• 229910019142 PO4 Inorganic materials 0.000 description 5
• 102100027467 Pro-opiomelanocortin Human genes 0.000 description 5
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
• 230000037396 body weight Effects 0.000 description 5
• 239000000872 buffer Substances 0.000 description 5
• 230000001054 cortical effect Effects 0.000 description 5
• IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 5
• 229960000258 corticotropin Drugs 0.000 description 5
• 206010012601 diabetes mellitus Diseases 0.000 description 5
• 230000004069 differentiation Effects 0.000 description 5
• 239000003814 drug Substances 0.000 description 5
• 239000012091 fetal bovine serum Substances 0.000 description 5
• 239000010408 film Substances 0.000 description 5
• 229940088597 hormone Drugs 0.000 description 5
• 239000005556 hormone Substances 0.000 description 5
• 239000010410 layer Substances 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 239000010452 phosphate Substances 0.000 description 5
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 108090000765 processed proteins & peptides Proteins 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 108090000623 proteins and genes Proteins 0.000 description 5
• 201000004700 rosacea Diseases 0.000 description 5
• 238000001356 surgical procedure Methods 0.000 description 5
• 238000002054 transplantation Methods 0.000 description 5
• WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 5
• 206010002091 Anaesthesia Diseases 0.000 description 4
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
• 206010036790 Productive cough Diseases 0.000 description 4
• 208000003251 Pruritus Diseases 0.000 description 4
• 208000027418 Wounds and injury Diseases 0.000 description 4
• 230000037005 anaesthesia Effects 0.000 description 4
• 239000007864 aqueous solution Substances 0.000 description 4
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
• 229910052794 bromium Inorganic materials 0.000 description 4
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
• 238000007906 compression Methods 0.000 description 4
• 230000006835 compression Effects 0.000 description 4
• 239000006071 cream Substances 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• 230000000762 glandular Effects 0.000 description 4
• 229910052736 halogen Inorganic materials 0.000 description 4
• 150000002367 halogens Chemical class 0.000 description 4
• 210000001320 hippocampus Anatomy 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 208000014674 injury Diseases 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 210000003205 muscle Anatomy 0.000 description 4
• 210000002241 neurite Anatomy 0.000 description 4
• 210000002569 neuron Anatomy 0.000 description 4
• VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 4
• 229910052757 nitrogen Inorganic materials 0.000 description 4
• 239000012044 organic layer Substances 0.000 description 4
• 239000000651 prodrug Substances 0.000 description 4
• 229940002612 prodrug Drugs 0.000 description 4
• 102000004169 proteins and genes Human genes 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 230000009759 skin aging Effects 0.000 description 4
• 239000011734 sodium Substances 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 210000003802 sputum Anatomy 0.000 description 4
• 208000024794 sputum Diseases 0.000 description 4
• 230000000638 stimulation Effects 0.000 description 4
• 238000003756 stirring Methods 0.000 description 4
• 229910052717 sulfur Inorganic materials 0.000 description 4
• 239000004094 surface-active agent Substances 0.000 description 4
• 208000011580 syndromic disease Diseases 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
• YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 206010029174 Nerve compression Diseases 0.000 description 3
• 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 3
• 241001303601 Rosacea Species 0.000 description 3
• 238000011579 SCID mouse model Methods 0.000 description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
• 229920002472 Starch Polymers 0.000 description 3
• BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
• 239000004164 Wax ester Substances 0.000 description 3
• 230000035508 accumulation Effects 0.000 description 3
• 238000009825 accumulation Methods 0.000 description 3
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 3
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 230000002354 daily effect Effects 0.000 description 3
• FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 3
• 208000035475 disorder Diseases 0.000 description 3
• PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
• 238000000605 extraction Methods 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 238000010438 heat treatment Methods 0.000 description 3
• 125000004446 heteroarylalkyl group Chemical group 0.000 description 3
• 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 3
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 230000002503 metabolic effect Effects 0.000 description 3
• 239000004530 micro-emulsion Substances 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 125000002950 monocyclic group Chemical group 0.000 description 3
• 230000014511 neuron projection development Effects 0.000 description 3
• 230000009871 nonspecific binding Effects 0.000 description 3
• 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 3
• 238000007911 parenteral administration Methods 0.000 description 3
• 239000002245 particle Substances 0.000 description 3
• 230000001575 pathological effect Effects 0.000 description 3
• 239000000813 peptide hormone Substances 0.000 description 3
• 239000002953 phosphate buffered saline Substances 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 102000004196 processed proteins & peptides Human genes 0.000 description 3
• 125000003226 pyrazolyl group Chemical group 0.000 description 3
• 230000002285 radioactive effect Effects 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
• 229940054269 sodium pyruvate Drugs 0.000 description 3
• 239000012265 solid product Substances 0.000 description 3
• 230000001148 spastic effect Effects 0.000 description 3
• 241000894007 species Species 0.000 description 3
• 229940031439 squalene Drugs 0.000 description 3
• TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
• 239000008107 starch Substances 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 239000000126 substance Substances 0.000 description 3
• 235000000346 sugar Nutrition 0.000 description 3
• 238000004809 thin layer chromatography Methods 0.000 description 3
• 150000003573 thiols Chemical class 0.000 description 3
• 239000003053 toxin Substances 0.000 description 3
• 231100000765 toxin Toxicity 0.000 description 3
• 108700012359 toxins Proteins 0.000 description 3
• 235000019386 wax ester Nutrition 0.000 description 3
• YHYKLKNNBYLTQY-UHFFFAOYSA-N 1,1-diphenylhydrazine Chemical compound C=1C=CC=CC=1N(N)C1=CC=CC=C1 YHYKLKNNBYLTQY-UHFFFAOYSA-N 0.000 description 2
• NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
• 241000416162 Astragalus gummifer Species 0.000 description 2
• 206010003694 Atrophy Diseases 0.000 description 2
• 206010061666 Autonomic neuropathy Diseases 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
• 206010008631 Cholera Diseases 0.000 description 2
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
• ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
• 240000007472 Leucaena leucocephala Species 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• 229940117029 Melanocortin receptor agonist Drugs 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• 229910002651 NO3 Inorganic materials 0.000 description 2
• 229910018954 NaNH2 Inorganic materials 0.000 description 2
• 208000028389 Nerve injury Diseases 0.000 description 2
• 108090000189 Neuropeptides Proteins 0.000 description 2
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
• 206010072139 Ocular rosacea Diseases 0.000 description 2
• 229930182555 Penicillin Natural products 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical group OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 229920001214 Polysorbate 60 Polymers 0.000 description 2
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
• NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 2
• 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
• 229920001615 Tragacanth Polymers 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 210000001789 adipocyte Anatomy 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 239000003513 alkali Substances 0.000 description 2
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• 230000037444 atrophy Effects 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 230000003542 behavioural effect Effects 0.000 description 2
• JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 125000002619 bicyclic group Chemical group 0.000 description 2
• 239000004305 biphenyl Substances 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 239000007975 buffered saline Substances 0.000 description 2
• 125000004432 carbon atom Chemical group C* 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 206010008118 cerebral infarction Diseases 0.000 description 2
• 235000012000 cholesterol Nutrition 0.000 description 2
• 150000001840 cholesterol esters Chemical class 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 229910052802 copper Inorganic materials 0.000 description 2
• 239000010949 copper Substances 0.000 description 2
• 239000012043 crude product Substances 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 230000007850 degeneration Effects 0.000 description 2
• 230000003412 degenerative effect Effects 0.000 description 2
• 208000002925 dental caries Diseases 0.000 description 2
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
• 210000002257 embryonic structure Anatomy 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 230000005284 excitation Effects 0.000 description 2
• 238000003818 flash chromatography Methods 0.000 description 2
• 239000013022 formulation composition Substances 0.000 description 2
• 239000012737 fresh medium Substances 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 125000000623 heterocyclic group Chemical group 0.000 description 2
• 239000008240 homogeneous mixture Substances 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• 210000003016 hypothalamus Anatomy 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 230000007803 itching Effects 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 230000002366 lipolytic effect Effects 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 239000007937 lozenge Substances 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 229940049920 malate Drugs 0.000 description 2
• 238000013289 male long evans rat Methods 0.000 description 2
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
• 239000000336 melanocortin receptor agonist Substances 0.000 description 2
• 201000001441 melanoma Diseases 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 229920000609 methyl cellulose Polymers 0.000 description 2
• 239000001923 methylcellulose Substances 0.000 description 2
• 235000010981 methylcellulose Nutrition 0.000 description 2
• 230000007659 motor function Effects 0.000 description 2
• 229920001206 natural gum Polymers 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 230000008764 nerve damage Effects 0.000 description 2
• 230000001537 neural effect Effects 0.000 description 2
• 230000004770 neurodegeneration Effects 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• VMPITZXILSNTON-UHFFFAOYSA-N o-anisidine Chemical compound COC1=CC=CC=C1N VMPITZXILSNTON-UHFFFAOYSA-N 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 239000006186 oral dosage form Substances 0.000 description 2
• IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
• 229940049954 penicillin Drugs 0.000 description 2
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
• 239000002304 perfume Substances 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 239000011148 porous material Substances 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
• 238000010992 reflux Methods 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 229910052707 ruthenium Inorganic materials 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 229920006395 saturated elastomer Polymers 0.000 description 2
• 239000002356 single layer Substances 0.000 description 2
• 206010040882 skin lesion Diseases 0.000 description 2
• 231100000444 skin lesion Toxicity 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 150000003385 sodium Chemical class 0.000 description 2
• 235000015424 sodium Nutrition 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 2
• JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 2
• 210000000278 spinal cord Anatomy 0.000 description 2
• 208000002320 spinal muscular atrophy Diseases 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 229910021653 sulphate ion Inorganic materials 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 239000011975 tartaric acid Substances 0.000 description 2
• 229960001367 tartaric acid Drugs 0.000 description 2
• 239000000196 tragacanth Substances 0.000 description 2
• 235000010487 tragacanth Nutrition 0.000 description 2
• 229940116362 tragacanth Drugs 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 230000007704 transition Effects 0.000 description 2
• URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
• DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
• WHNFPRLDDSXQCL-UHFFFAOYSA-N α-melanotropin Chemical compound C=1N=CNC=1CC(C(=O)NC(CC=1C=CC=CC=1)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)NC(CCCCN)C(=O)N1C(CCC1)C(=O)NC(C(C)C)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(NC(=O)C(CO)NC(C)=O)CC1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UHFFFAOYSA-N 0.000 description 2
• RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
• QUCFVNGGGFLOES-ACQYNFKHSA-N (4s)-5-[[(2s)-1-[[(2s)-1-[[(2r)-6-amino-1-[[(1s)-1-carboxy-2-phenylethyl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-[[(2s)-2-amino-4-methylsulfonylbutanoyl]amino]-5-oxopentanoic acid Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCS(=O)(=O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CN=CN1 QUCFVNGGGFLOES-ACQYNFKHSA-N 0.000 description 1
• VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
• WDZRDJVJZOCAME-UHFFFAOYSA-N 1-(2-methoxyphenyl)-1-phenylhydrazine Chemical compound COC1=CC=CC=C1N(N)C1=CC=CC=C1 WDZRDJVJZOCAME-UHFFFAOYSA-N 0.000 description 1
• CGOKGYURRMROFW-UHFFFAOYSA-N 1-(2-methylphenyl)-1-phenylhydrazine Chemical compound CC1=CC=CC=C1N(N)C1=CC=CC=C1 CGOKGYURRMROFW-UHFFFAOYSA-N 0.000 description 1
• VIWNHFYPDBGZDC-UHFFFAOYSA-N 1-(2-phenylphenyl)-9H-fluorene Chemical compound C=12CC3=CC=CC=C3C2=CC=CC=1C1=CC=CC=C1C1=CC=CC=C1 VIWNHFYPDBGZDC-UHFFFAOYSA-N 0.000 description 1
• 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
• ABQKHKWXTUVKGF-UHFFFAOYSA-N 1-isothiocyanato-4-methylbenzene Chemical compound CC1=CC=C(N=C=S)C=C1 ABQKHKWXTUVKGF-UHFFFAOYSA-N 0.000 description 1
• 125000006023 1-pentenyl group Chemical group 0.000 description 1
• 125000006017 1-propenyl group Chemical group 0.000 description 1
• VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
• NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
• TYIOVYZMKITKRO-UHFFFAOYSA-N 2-[hexadecyl(dimethyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CC([O-])=O TYIOVYZMKITKRO-UHFFFAOYSA-N 0.000 description 1
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
• 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
• 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• BYMHPNQECCIGDF-UHFFFAOYSA-N 2-hydroxysulfanylethanol Chemical compound OCCSO BYMHPNQECCIGDF-UHFFFAOYSA-N 0.000 description 1
• FSTPMFASNVISBU-UHFFFAOYSA-N 2-methoxybenzonitrile Chemical compound COC1=CC=CC=C1C#N FSTPMFASNVISBU-UHFFFAOYSA-N 0.000 description 1
• 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 description 1
• IVNOKZUKBMNYLB-UHFFFAOYSA-N 2-naphthalen-1-ylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C3=CC=CC=C3C=CC=2)=C1 IVNOKZUKBMNYLB-UHFFFAOYSA-N 0.000 description 1
• 125000006024 2-pentenyl group Chemical group 0.000 description 1
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
• MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
• 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 241000321096 Adenoides Species 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 102000006822 Agouti Signaling Protein Human genes 0.000 description 1
• 108010072151 Agouti Signaling Protein Proteins 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 235000017060 Arachis glabrata Nutrition 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• 235000010777 Arachis hypogaea Nutrition 0.000 description 1
• 235000018262 Arachis monticola Nutrition 0.000 description 1
• 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
• 201000006474 Brain Ischemia Diseases 0.000 description 1
• 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
• PMEIDXFKYZAEJM-UHFFFAOYSA-N C(=O)(C(=C)C)C=1C(=C(C=CC1)O)CCCCCCCCCC Chemical compound C(=O)(C(=C)C)C=1C(=C(C=CC1)O)CCCCCCCCCC PMEIDXFKYZAEJM-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 208000015879 Cerebellar disease Diseases 0.000 description 1
• 206010008120 Cerebral ischaemia Diseases 0.000 description 1
• 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
• 102000009016 Cholera Toxin Human genes 0.000 description 1
• 108010049048 Cholera Toxin Proteins 0.000 description 1
• 241000251730 Chondrichthyes Species 0.000 description 1
• 108090000317 Chymotrypsin Proteins 0.000 description 1
• 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 description 1
• 208000034656 Contusions Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 241000484025 Cuniculus Species 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
• MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• 208000012184 Diffuse Brain injury Diseases 0.000 description 1
• QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 102400001368 Epidermal growth factor Human genes 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• 206010015548 Euthanasia Diseases 0.000 description 1
• 208000001730 Familial dysautonomia Diseases 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 206010016818 Fluorosis Diseases 0.000 description 1
• 108091006027 G proteins Proteins 0.000 description 1
• 102000030782 GTP binding Human genes 0.000 description 1
• 108091000058 GTP-Binding Proteins 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 description 1
• 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 241000282575 Gorilla Species 0.000 description 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
• 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
• 208000010496 Heart Arrest Diseases 0.000 description 1
• 108010034791 Heterochromatin Proteins 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000978422 Homo sapiens Melanocortin receptor 5 Proteins 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 241000243251 Hydra Species 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 206010062767 Hypophysitis Diseases 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 206010062717 Increased upper airway secretion Diseases 0.000 description 1
• 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
• 235000010254 Jasminum officinale Nutrition 0.000 description 1
• 240000005385 Jasminum sambac Species 0.000 description 1
• 208000027747 Kennedy disease Diseases 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• 229930195714 L-glutamate Natural products 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• 208000034693 Laceration Diseases 0.000 description 1
• 241001460053 Laides Species 0.000 description 1
• 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
• 208000009829 Lewy Body Disease Diseases 0.000 description 1
• 241000428198 Lutrinae Species 0.000 description 1
• 208000019090 Machado-Joseph disease type 3 Diseases 0.000 description 1
• 101710085771 Melanocortin receptor 5 Proteins 0.000 description 1
• 102100023723 Melanocortin receptor 5 Human genes 0.000 description 1
• 102400000747 Melanocyte-stimulating hormone beta Human genes 0.000 description 1
• 101710129905 Melanotropin beta Proteins 0.000 description 1
• 240000008821 Menyanthes trifoliata Species 0.000 description 1
• 235000011779 Menyanthes trifoliata Nutrition 0.000 description 1
• 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
• 108090000192 Methionyl aminopeptidases Proteins 0.000 description 1
• 102000029749 Microtubule Human genes 0.000 description 1
• 108091022875 Microtubule Proteins 0.000 description 1
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
• 208000026072 Motor neurone disease Diseases 0.000 description 1
• 206010028289 Muscle atrophy Diseases 0.000 description 1
• JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Substances ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 1
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
• 206010028980 Neoplasm Diseases 0.000 description 1
• 102000003797 Neuropeptides Human genes 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 241000819999 Nymphes Species 0.000 description 1
• REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
• 108010038109 Org 2766 Proteins 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 208000031481 Pathologic Constriction Diseases 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 229930182556 Polyacetal Natural products 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 208000032225 Proximal spinal muscular atrophy type 1 Diseases 0.000 description 1
• 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 description 1
• 206010037779 Radiculopathy Diseases 0.000 description 1
• 208000005587 Refsum Disease Diseases 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• 201000001638 Riley-Day syndrome Diseases 0.000 description 1
• KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 241000555745 Sciuridae Species 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
• 201000001880 Sexual dysfunction Diseases 0.000 description 1
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
• 206010072170 Skin wound Diseases 0.000 description 1
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
• 206010041235 Snoring Diseases 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
• BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 206010069689 Spinal column injury Diseases 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 102000007451 Steroid Receptors Human genes 0.000 description 1
• 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
• 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• 239000005864 Sulphur Substances 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 206010043189 Telangiectasia Diseases 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
• 208000000323 Tourette Syndrome Diseases 0.000 description 1
• 208000030886 Traumatic Brain injury Diseases 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 229940122618 Trypsin inhibitor Drugs 0.000 description 1
• 101710162629 Trypsin inhibitor Proteins 0.000 description 1
• IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 241000607626 Vibrio cholerae Species 0.000 description 1
• 208000026481 Werdnig-Hoffmann disease Diseases 0.000 description 1
• 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
• 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• ZJZYBETXLHBPBZ-UHFFFAOYSA-K [F-].[F-].[F-].[Sb+3]=O Chemical compound [F-].[F-].[F-].[Sb+3]=O ZJZYBETXLHBPBZ-UHFFFAOYSA-K 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 229940022663 acetate Drugs 0.000 description 1
• 235000011054 acetic acid Nutrition 0.000 description 1
• DRFCSTAUJQILHC-UHFFFAOYSA-N acetic acid;benzoic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1 DRFCSTAUJQILHC-UHFFFAOYSA-N 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 210000002534 adenoid Anatomy 0.000 description 1
• UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
• 102000030621 adenylate cyclase Human genes 0.000 description 1
• 108060000200 adenylate cyclase Proteins 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 230000001919 adrenal effect Effects 0.000 description 1
• 208000030597 adult Refsum disease Diseases 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 150000001336 alkenes Chemical class 0.000 description 1
• 150000001345 alkine derivatives Chemical class 0.000 description 1
• 150000001350 alkyl halides Chemical class 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Natural products C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
• 230000003255 anti-acne Effects 0.000 description 1
• 230000001857 anti-mycotic effect Effects 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 239000002543 antimycotic Substances 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 229910052786 argon Inorganic materials 0.000 description 1
• 125000005418 aryl aryl group Chemical group 0.000 description 1
• 210000003050 axon Anatomy 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 239000003855 balanced salt solution Substances 0.000 description 1
• 235000021168 barbecue Nutrition 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 239000000440 bentonite Substances 0.000 description 1
• 229910000278 bentonite Inorganic materials 0.000 description 1
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 229920002988 biodegradable polymer Polymers 0.000 description 1
• 239000004621 biodegradable polymer Substances 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 229920001400 block copolymer Polymers 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 229940006460 bromide ion Drugs 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 239000000337 buffer salt Substances 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 238000001354 calcination Methods 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 235000011148 calcium chloride Nutrition 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229960001631 carbomer Drugs 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 238000002701 cell growth assay Methods 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000007969 cellular immunity Effects 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 208000026106 cerebrovascular disease Diseases 0.000 description 1
• 229940081733 cetearyl alcohol Drugs 0.000 description 1
• 229940056318 ceteth-20 Drugs 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
• 125000000068 chlorophenyl group Chemical group 0.000 description 1
• 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
• 229960002376 chymotrypsin Drugs 0.000 description 1
• 229940001468 citrate Drugs 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 239000000084 colloidal system Substances 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 229940125810 compound 20 Drugs 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 230000009519 contusion Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 230000009537 cortical lesion Effects 0.000 description 1
• 108091008723 corticosteroid receptors Proteins 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 229940095074 cyclic amp Drugs 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 229960001270 d- tartaric acid Drugs 0.000 description 1
• 125000006612 decyloxy group Chemical group 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 239000003405 delayed action preparation Substances 0.000 description 1
• 230000003210 demyelinating effect Effects 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 208000004042 dental fluorosis Diseases 0.000 description 1
• 229960003964 deoxycholic acid Drugs 0.000 description 1
• 239000007933 dermal patch Substances 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 238000004031 devitrification Methods 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 125000005265 dialkylamine group Chemical group 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 230000009699 differential effect Effects 0.000 description 1
• UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
• UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 108010007093 dispase Proteins 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 229930004069 diterpene Natural products 0.000 description 1
• 150000004141 diterpene derivatives Chemical class 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 235000013399 edible fruits Nutrition 0.000 description 1
• 230000002900 effect on cell Effects 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 238000009505 enteric coating Methods 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 229960003276 erythromycin Drugs 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 235000019439 ethyl acetate Nutrition 0.000 description 1
• FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical group CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
• 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 238000004299 exfoliation Methods 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 210000003499 exocrine gland Anatomy 0.000 description 1
• 238000013401 experimental design Methods 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 235000021050 feed intake Nutrition 0.000 description 1
• 230000004634 feeding behavior Effects 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 239000007941 film coated tablet Substances 0.000 description 1
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 238000001640 fractional crystallisation Methods 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 230000007849 functional defect Effects 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 230000008570 general process Effects 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 239000003292 glue Substances 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 239000001087 glyceryl triacetate Substances 0.000 description 1
• 235000013773 glyceryl triacetate Nutrition 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• 150000002338 glycosides Chemical class 0.000 description 1
• 239000003163 gonadal steroid hormone Substances 0.000 description 1
• 239000003979 granulating agent Substances 0.000 description 1
• JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
• DXTIKTAIYCJTII-UHFFFAOYSA-N guanidine acetate Chemical compound CC([O-])=O.NC([NH3+])=N DXTIKTAIYCJTII-UHFFFAOYSA-N 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 208000014617 hemorrhoid Diseases 0.000 description 1
• 125000004404 heteroalkyl group Chemical group 0.000 description 1
• 210000004458 heterochromatin Anatomy 0.000 description 1
• UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
• 150000007857 hydrazones Chemical class 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• 108010046780 hydrocortisone receptor Proteins 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
• 125000002632 imidazolidinyl group Chemical group 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 230000003053 immunization Effects 0.000 description 1
• 230000007813 immunodeficiency Effects 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 229940027941 immunoglobulin g Drugs 0.000 description 1
• 238000013388 immunohistochemistry analysis Methods 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 239000005414 inactive ingredient Substances 0.000 description 1
• 230000007574 infarction Effects 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 206010022437 insomnia Diseases 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
• 229940006461 iodide ion Drugs 0.000 description 1
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 208000037906 ischaemic injury Diseases 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 229960002725 isoflurane Drugs 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 239000010977 jade Substances 0.000 description 1
• 201000004815 juvenile spinal muscular atrophy Diseases 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 229940015418 ketaset Drugs 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 206010023497 kuru Diseases 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 229940001447 lactate Drugs 0.000 description 1
• 208000036546 leukodystrophy Diseases 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 230000004130 lipolysis Effects 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 235000012054 meals Nutrition 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
• 210000004688 microtubule Anatomy 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 208000005264 motor neuron disease Diseases 0.000 description 1
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
• 230000020763 muscle atrophy Effects 0.000 description 1
• 201000000585 muscular atrophy Diseases 0.000 description 1
• 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 210000001577 neostriatum Anatomy 0.000 description 1
• 230000005709 nerve cell growth Effects 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 230000002232 neuromuscular Effects 0.000 description 1
• 230000016273 neuron death Effects 0.000 description 1
• 230000003961 neuronal insult Effects 0.000 description 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
• SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical class CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
• 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 208000031237 olivopontocerebellar atrophy Diseases 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 229910052762 osmium Inorganic materials 0.000 description 1
• SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 150000002923 oximes Chemical class 0.000 description 1
• 208000021090 palsy Diseases 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 239000003182 parenteral nutrition solution Substances 0.000 description 1
• 231100000915 pathological change Toxicity 0.000 description 1
• 230000036285 pathological change Effects 0.000 description 1
• 235000020232 peanut Nutrition 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 239000003961 penetration enhancing agent Substances 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 239000008024 pharmaceutical diluent Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 229940067157 phenylhydrazine Drugs 0.000 description 1
• 229940117953 phenylisothiocyanate Drugs 0.000 description 1
• 125000004344 phenylpropyl group Chemical group 0.000 description 1
• 208000026435 phlegm Diseases 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 230000019612 pigmentation Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 210000003635 pituitary gland Anatomy 0.000 description 1
• 229920001992 poloxamer 407 Polymers 0.000 description 1
• 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 239000002745 poly(ortho ester) Substances 0.000 description 1
• 229920001610 polycaprolactone Polymers 0.000 description 1
• 239000004632 polycaprolactone Substances 0.000 description 1
• 229920002721 polycyanoacrylate Polymers 0.000 description 1
• 125000003367 polycyclic group Chemical group 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
• 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
• 229920006324 polyoxymethylene Polymers 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229940113124 polysorbate 60 Drugs 0.000 description 1
• 229920002102 polyvinyl toluene Polymers 0.000 description 1
• 150000004032 porphyrins Chemical class 0.000 description 1
• 238000004237 preparative chromatography Methods 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 208000001282 primary progressive aphasia Diseases 0.000 description 1
• 208000032207 progressive 1 supranuclear palsy Diseases 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
• 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000006239 protecting group Chemical group 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 201000000196 pseudobulbar palsy Diseases 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 238000004445 quantitative analysis Methods 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 239000011535 reaction buffer Substances 0.000 description 1
• 230000007420 reactivation Effects 0.000 description 1
• 229940044601 receptor agonist Drugs 0.000 description 1
• 239000000018 receptor agonist Substances 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 238000001525 receptor binding assay Methods 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000001172 regenerating effect Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000010410 reperfusion Effects 0.000 description 1
• 238000009256 replacement therapy Methods 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 229940069575 rompun Drugs 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical group OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 1
• 238000007790 scraping Methods 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 229910052711 selenium Inorganic materials 0.000 description 1
• 239000011669 selenium Substances 0.000 description 1
• 210000001044 sensory neuron Anatomy 0.000 description 1
• 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 239000012679 serum free medium Substances 0.000 description 1
• 231100000872 sexual dysfunction Toxicity 0.000 description 1
• 229910052709 silver Inorganic materials 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• 210000004927 skin cell Anatomy 0.000 description 1
• 230000036620 skin dryness Effects 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
• 239000004324 sodium propionate Substances 0.000 description 1
• 235000010334 sodium propionate Nutrition 0.000 description 1
• 229960003212 sodium propionate Drugs 0.000 description 1
• 229940074404 sodium succinate Drugs 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 229950004959 sorbitan oleate Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 210000005250 spinal neuron Anatomy 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 238000012453 sprague-dawley rat model Methods 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000036262 stenosis Effects 0.000 description 1
• 208000037804 stenosis Diseases 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
• 230000003637 steroidlike Effects 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 159000000008 strontium salts Chemical class 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 210000003523 substantia nigra Anatomy 0.000 description 1
• 125000003107 substituted aryl group Chemical group 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 230000000475 sunscreen effect Effects 0.000 description 1
• 239000000516 sunscreening agent Substances 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 210000000106 sweat gland Anatomy 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 238000001308 synthesis method Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 208000009056 telangiectasis Diseases 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 229960003604 testosterone Drugs 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
• 230000001732 thrombotic effect Effects 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 230000037317 transdermal delivery Effects 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• 229960002622 triacetin Drugs 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 239000002753 trypsin inhibitor Substances 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 208000032471 type 1 spinal muscular atrophy Diseases 0.000 description 1
• 208000032527 type III spinal muscular atrophy Diseases 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 230000006492 vascular dysfunction Effects 0.000 description 1
• 229940118696 vibrio cholerae Drugs 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1
• 239000000230 xanthan gum Substances 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• 235000010493 xanthan gum Nutrition 0.000 description 1
• 229940082509 xanthan gum Drugs 0.000 description 1
• 238000002689 xenotransplantation Methods 0.000 description 1
• QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
• SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 1
• 229930195724 β-lactose Natural products 0.000 description 1
• 229940124648 γ-Secretase Modulator Drugs 0.000 description 1